Adrenal mass is a common disease in urologic clinic. For big tumors or tumors with endocrine functions, surgery is still the standard of care. With the development of minimally invasive techniques, the surgical management of adrenal masses has been greatly simplified. Large incisions are replaced and exposure of the surgical field is improved significantly. As […]
San Francisco, CA (UroToday.com) — Verb Surgical, the discreet robotic surgery joint venture from Verily and Johnson & Johnson, has tapped Kurt Azarbarzin to be its president and CEO, effective immediately.
Male stress urinary incontinence (SUI) represents a complication after radical prostatectomy or benign prostatic obstruction surgery. The artificial urinary sphincter is considered the standard treatment but interest on minimally invasive devices, such as adjustable balloons, has recently increased. Aim of this study is to evaluate the efficacy and safety of the ProACT system. In this […]
Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA] Condition: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7 Intervention: Drug: Nivolumab Radiation: Radiation Purpose: This […]
Biomarker Discovery Study to Identify Patients With Advanced Urothelial Cancer Benefitting From Pembrolizumab Treatment Condition: Transitional Cell Carcinoma of the Bladder, Biomarkers Intervention: Drug: Pembrolizumab Purpose: In the RESPONDER study, the role of the immune evasive mechanisms combined with genomic characterization will be explored in urothelial cancer patients treated with second-line treatment with pembrolizumab. Combined […]
A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined With ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder Condition: Urinary Bladder Cancer Intervention: Drug: Nivolumab Radiation: Radiation therapy of the pelvis Procedure: Radical cystectomy with standardized pelvic lymphadenectomy Purpose: A prospective, single arm, […]
Phase 1 Study of the Combination of CM082 With Everolimus in Patients With Metastatic Renal Cell Carcinoma (RCC): Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy Condition: Renal Cell Carcinoma Recurrent Intervention: Drug: CM082 Drug: Everolimus Purpose: This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination […]
Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy Condition: Prostate Cancer Intervention: Drug: Goserelin Drug: Prednisone Drug: Abiraterone Drug: Apalutamide Purpose: This is a randomized study to evaluate the efficacy and safety neoadjuvant androgen deprivation therapy with goserelin […]
Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer Condition: Prostate Cancer Intervention: Radiation: Radiotherapy to the pelvis Drug: Hormonal therapy (LHRH agonist and/or antiandrogens) Purpose: PART I Hormone therapy with or without definitive radiotherapy in metastatic prostate cancer The goal of this clinical study PART I is to determine impact of radiotherapy […]
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer Condition: Prostate Cancer Intervention: Drug: Enoblituzumab Purpose: This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical prostatectomy. Study Type: Interventional Clinical Trials […]
